What is the recommended starting dose and titration schedule of lemborexant in adults?

Lemborexant Dosing for Insomnia in Adults

The recommended starting dose of lemborexant is 5 mg once nightly, taken no more than once per night and within 7 hours of planned awakening, with a maximum dose of 10 mg if needed for insufficient response. 1

Starting Dose and Administration

• Initial dose: 5 mg orally once per night 1, 2
• Take within 7 hours of planned awakening
• Can be taken with or without food
• Administer no more than once per night

Dose Titration

If 5 mg provides insufficient benefit, the dose may be increased to 10 mg once nightly. 1, 3 However, evidence suggests the 10 mg dose offers only minimal additional improvement in sleep metrics over 5 mg while significantly increasing the risk of somnolence 4. The 10 mg dose should be reserved for patients who have demonstrated inadequate response to 5 mg rather than used as a first-line starting dose 4.

Key Dosing Considerations

Drug Interactions (Critical)

Avoid concomitant use with moderate or strong CYP3A4 inhibitors 1, 2:

• Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole): Avoid combination entirely 1
• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin, verapamil):
  • Fluconazole increases lemborexant exposure by approximately 4.2-fold (AUC) and 1.6-fold (Cmax) 1
  • Maximum dose should not exceed 5 mg when used with moderate inhibitors 2
  • In some countries where 2.5 mg is available, this lower dose should be used 2
• Weak CYP3A4 inhibitors (e.g., fluoxetine, ranitidine): Maximum recommended dose is 5 mg 2

Special Populations

Hepatic impairment:

• Mild hepatic impairment: Standard dosing acceptable
• Moderate hepatic impairment: Maximum dose 5 mg once daily 5
• Severe hepatic impairment: Maximum dose 5 mg once daily (AUC increases 2.08-fold) 5

Renal impairment: No specific dose adjustments mentioned in the evidence, though lemborexant is primarily metabolized hepatically via CYP3A4/5 3

Elderly patients: No specific dose reduction required based on age alone 3

Efficacy Data

Both 5 mg and 10 mg doses demonstrate efficacy for insomnia:

• Sleep onset latency reduction: 9.23 minutes (5 mg) and 12.56 minutes (10 mg) vs placebo 6
• Wake after sleep onset reduction: 19.9 minutes (5 mg) and 22.24 minutes (10 mg) vs placebo 6
• Sleep efficiency improvement: 6.08% (5 mg) and 7.46% (10 mg) vs placebo 6
• Sustained efficacy demonstrated beyond 6 months 3

Safety Profile

Common adverse effects:

• Somnolence: ~10% at 10 mg (significantly higher than placebo, RR = 4.95) 3, 6
• Headache: 2-5% 3
• Nightmares: 2-5% 3

Serious but rare adverse effects:

• Sleep paralysis
• Hypnagogic/hypnopompic hallucinations
• Cataplexy-like symptoms
• Complex sleep behaviors
• Emergence of depression/suicidal ideation 3

Important safety notes:

• No evidence of tolerance or withdrawal effects on discontinuation 3
• Treatment-emergent adverse events are significantly more common than placebo (RR = 1.94) 6

Clinical Pearls

• The 5 mg dose provides a favorable risk-benefit ratio for most patients, with the 10 mg dose offering marginal additional benefit at the cost of increased somnolence 4
• Lemborexant has a half-life of 17-19 hours, which is longer than suvorexant (12 hours) 3
• Peak plasma concentration occurs 1-3 hours after administration 3
• Unlike benzodiazepines, lemborexant works by blocking orexin receptors that promote wakefulness rather than enhancing GABA activity